Yes, semaglutide (made by Novo Nordisk, brand names Ozempic, Wegovy) is a GLP-1 agonist; tirzepatide (made by Eli Lilly, brand names Mounjaro, Zepbound) is a dual GLP-1 and GIP agonist. Tirzepatide is newer and more effective, otherwise they're very similar - once a week injection, significantly reduces appetite, the use cases are diabetes and weight loss. Eli Lilly also have retatrutide in their pipeline which is a triple (GLP-1, GIP, glucagon) agonist, and which will likely be even better and will be available in a couple of years.